Americans prepare for another surge in cases, vaccine and treatment approval moves forward, and new partnerships curb coronavirus misinformation. Here’s what you should know:
Want to receive this weekly roundup and other coronavirus news? Sign up here!
What we know about coronavirus as cases climb once again
This week the virus continued to surge throughout much of the United States and Europe. Yesterday, several European countries, including Italy and Austria, reported their highest single-day cases. And stateside, it was the first day with more than 70,000 new cases since the summer, as 32 states reported rising rates of infection.
While the subject of how and whether to reopen schools remains controversial, experts say that so far there’s little to suggest that reopened schools are contributing to these surges. And though infections are rising, Covid-19 death rates have plummeted, an indication that doctors are getting better at caring for patients even in the absence of a definitive cure or treatment.
We also know much more about how the virus spreads than we did in the pandemic’s early days. While it can linger on surfaces, mounting evidence shows that you’re far less likely to catch it from touching something than you are from neglecting to social distance. Earlier this week, the CDC modified its guidelines to reflect research showing one can contract coronavirus from multiple brief encounters. The agency now defines a “close contact” as spending a cumulative 15 minutes or more within 6 feet of an infectious person over a period of 24 hours.
A vaccine advances as America’s first treatment is greenlit
Yesterday, Moderna announced that it had enrolled all 30,000 participants in its Phase III vaccine trial. More than a third are minorities and a quarter are over the age of 65 in an attempt to reflect the diversity of the general population. The company expects to have early data about the efficacy of its vaccine in the next month. During a daylong meeting with FDA officials the same day, some vaccine experts urged the agency to request more than the requisite two months of safety data before approving vaccines.
The FDA has also moved forward with remdesivir as the first—and only—fully approved drug for treating Covid-19 in the US. The drug was granted emergency use authorization in May, and has been approved or authorized for temporary use in around 50 countries. Now, it can be used for any hospitalized Covid-19 patient in the US who’s at least 12 years old. This news comes approximately a week after a massive international trial found that remdesivir does not prevent deaths among patients with severe cases with Covid-19. The research has not yet been peer reviewed or published in a journal, and some have disputed its conclusiveness. But the trial’s sheer size suggests that the data are still significant.